Thematics Asset Management Decreases Position in CryoPort, Inc. $CYRX

Thematics Asset Management trimmed its position in CryoPort, Inc. (NASDAQ:CYRX) by 14.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,638,623 shares of the company’s stock after selling 276,262 shares during the quarter. Thematics Asset Management’s holdings in CryoPort were worth $15,534,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new position in shares of CryoPort in the third quarter valued at approximately $756,000. Bullseye Asset Management LLC increased its position in shares of CryoPort by 14.0% during the third quarter. Bullseye Asset Management LLC now owns 296,574 shares of the company’s stock worth $2,811,000 after purchasing an additional 36,406 shares in the last quarter. UBS Group AG increased its position in shares of CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after purchasing an additional 705,649 shares in the last quarter. BNP Paribas Financial Markets raised its stake in CryoPort by 55.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after purchasing an additional 4,225 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in CryoPort by 33.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 54,060 shares of the company’s stock valued at $512,000 after purchasing an additional 13,559 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Stock Performance

NASDAQ:CYRX opened at $7.82 on Friday. CryoPort, Inc. has a one year low of $4.63 and a one year high of $11.45. The stock has a market cap of $389.91 million, a PE ratio of 5.92 and a beta of 1.69. The stock has a 50 day moving average price of $9.26 and a 200 day moving average price of $9.36.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The company had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. As a group, analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on CYRX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Wall Street Zen cut shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC raised their price target on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CryoPort currently has an average rating of “Moderate Buy” and a consensus target price of $12.94.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.